Home Prognostic significance of soluble CD25 in patients with sepsis: a prospective observational study
Article
Licensed
Unlicensed Requires Authentication

Prognostic significance of soluble CD25 in patients with sepsis: a prospective observational study

  • Chun-Mei Huang , Xin-Jie Xu ORCID logo , Wen-Qi Qi and Qin-Min Ge EMAIL logo
Published/Copyright: February 28, 2022

Abstract

Objectives

The diagnosis of sepsis is challenging, the need for sensitive and specific diagnostic and prognostic biomarkers has not been met. Soluble CD25 (sCD25) is a readily available biomarker reported to represent the severity of the disease. This study aimed to assess the association between sCD25 and mortality in patients with sepsis.

Methods

In total, 329 adult patients with sepsis were screened through a prospective, observational study. We investigated the severity scores and sCD25 levels at admission to the intensive care unit (ICU), defined by sepsis (sepsis-3). The prognostic value of sCD25 was assessed using receiver operating characteristic (ROC) curves and binary logistic regression models in predicting unfavourable outcome. The correlations between variables and severity of disease were analysed by Spearman correlation tests.

Results

After entering the ICU, the sCD25 level and sequential organ failure assessment (SOFA) score were significantly higher in nonsurvivors than in survivors. The prognostic values estimated by the ROC curves were 0.678 for sCD25 and 0.945 for SOFA score at ICU admission. sCD25 had a modest ability to predict poor outcome. Logistic regression showed that increased levels of sCD25 were independently associated with unfavourable outcome. Spearman correlation tests showed that sCD25 levels were positively correlated with disease severity.

Conclusions

In sepsis patients, increased sCD25 levels were independently associated with poor clinical outcomes. Further research is needed to improve the understanding of the pathophysiology of this relationship.


Corresponding author: Qin-Min Ge, Department of Emergency, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200092, P.R. China, E-mail:
Chun-Mei Huang, Xin-Jie Xu and Wen-Qi Qi have contributed equally to this work and should be considered co-first authors.

Acknowledgments

We thank the Emergency Department of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine for its comprehensive support for this study.

  1. Research funding: None declared.

  2. Author contribution: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: The study was approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine and was carried out in accordance with the Declaration of Helsinki. All data were anonymized.

References

1. Singer, M, Deutschman, CS, Seymour, CW, Shankar-Hari, M, Annane, D, Bauer, M, et al.. The Third international Consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315:801–10, https://doi.org/10.1001/jama.2016.0287.Search in Google Scholar

2. Cecconi, M, Evans, L, Levy, M, Rhodes, A. Sepsis and septic shock. Lancet 2018;392:75–87, https://doi.org/10.1016/s0140-6736(18)30696-2.Search in Google Scholar

3. Dombrovskiy, VY, Martin, AA, Sunderram, J, Paz, HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007;35:1244–50, https://doi.org/10.1097/01.ccm.0000261890.41311.e9.Search in Google Scholar

4. Remick, DG. Pathophysiology of sepsis. Am J Pathol 2007;170:1435–44, https://doi.org/10.2353/ajpath.2007.060872.Search in Google Scholar PubMed PubMed Central

5. Monneret, G, Venet, F, Pachot, A, Lepape, A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 2008;14:64–78, https://doi.org/10.2119/2007-00102.Monneret.Search in Google Scholar PubMed PubMed Central

6. Becker, KL, Snider, R, Nylen, ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 2008;36:941–52, https://doi.org/10.1097/ccm.0b013e318165babb.Search in Google Scholar

7. Maruna, P, Nedelnikova, K, Gurlich, R. Physiology and genetics of procalcitonin. Physiol Res 2000;49:S57–61.Search in Google Scholar

8. Povoa, P. C-reactive protein: a valuable marker of sepsis. Intensive Care Med 2002;28:235–43, https://doi.org/10.1007/s00134-002-1209-6.Search in Google Scholar PubMed

9. Spapen, HD, Hachimi-Idrissi, S, Corne, L, Huyghens, LP. Diagnostic markers of sepsis in the emergency department. Acta Clin Belg 2006;61:138–42, https://doi.org/10.1179/acb.2006.022.Search in Google Scholar PubMed

10. Pierrakos, C, Vincent, JL. Sepsis biomarkers: a review. Crit Care 2010;14:R15, https://doi.org/10.1186/cc8872.Search in Google Scholar PubMed PubMed Central

11. Jensen, JU, Hein, L, Lundgren, B, Bestle, MH, Mohr, TT, Andersen, MH, et al.. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med 2011;39:2048–58, https://doi.org/10.1097/ccm.0b013e31821e8791.Search in Google Scholar PubMed

12. Bouadma, L, Luyt, CE, Tubach, F, Cracco, C, Alvarez, A, Schwebel, C, et al.. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375:463–74, https://doi.org/10.1016/s0140-6736(09)61879-1.Search in Google Scholar

13. Cohen, J. The immunopathogenesis of sepsis. Nature 2002;420:885–91, https://doi.org/10.1038/nature01326.Search in Google Scholar PubMed

14. Hotchkiss, RS, Karl, IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138–50, https://doi.org/10.1056/nejmra021333.Search in Google Scholar PubMed

15. Rubin, LA, Kurman, CC, Fritz, ME, Biddison, WE, Boutin, B, Yarchoan, R, et al.. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985;135:3172–7.10.4049/jimmunol.135.5.3172Search in Google Scholar

16. von Bahr Greenwood, T, Palmkvist-Kaijser, K, Chiang, SC, Tesi, B, Bryceson, YT, Hjelmqvist, H, et al.. Elevated ferritin and soluble CD25 in critically ill patients are associated with parameters of (hyper) inflammation and lymphocyte cytotoxicity. Minerva Anestesiol 2019;85:1289–98. https://doi.org/10.23736/S0375-9393.19.13534-1.Search in Google Scholar PubMed

17. de Guadiana-Romualdo, LG, Berger, M, Jiménez-Santos, E, Rebollo-Acebes, S, Jiménez-Sánchez, R, Esteban-Torrella, P, et al.. Pancreatic stone protein and soluble CD25 for infection and sepsis in an emergency department. Eur J Clin Invest 2017;47:297–304. https://doi.org/10.1111/eci.12732.Search in Google Scholar PubMed

18. Saito, K, Wagatsuma, T, Toyama, H, Ejima, Y, Hoshi, K, Shibusawa, M, et al.. Sepsis is characterized by the increases in percentages of circulating CD4+CD25+ regulatory T cells and plasma levels of soluble CD25. Tohoku J Exp Med 2008;216:61–8, https://doi.org/10.1620/tjem.216.61.Search in Google Scholar PubMed

19. Hosomi, S, Yamagami, H, Itani, S, Yukawa, T, Otani, K, Nagami, Y, et al.. Sepsis markers soluble IL-2 receptor and soluble CD14 subtype as potential biomarkers for complete mucosal healing in patients with inflammatory Bowel disease. J Crohns Colitis 2018;12:87–95. https://doi.org/10.1093/ecco-jcc/jjx124.Search in Google Scholar PubMed

20. Garcia de Guadiana-Romualdo, L, Berger, M, Jimenez-Santos, E, Rebollo-Acebes, S, Jimenez-Sanchez, R, Esteban-Torrella, P, et al.. Pancreatic stone protein and soluble CD25 for infection and sepsis in an emergency department. Eur J Clin Invest 2017;47:297–304, https://doi.org/10.1111/eci.12732.Search in Google Scholar

21. Gaieski, DF, Edwards, JM, Kallan, MJ, Carr, BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 2013;41:1167–74, https://doi.org/10.1097/ccm.0b013e31827c09f8.Search in Google Scholar

22. Rudd, KE, Kissoon, N, Limmathurotsakul, D, Bory, S, Mutahunga, B, Seymour, CW, et al.. The global burden of sepsis: barriers and potential solutions. Crit Care 2018;22:232, https://doi.org/10.1186/s13054-018-2157-z.Search in Google Scholar PubMed PubMed Central

23. Harrison, DA, Welch, CA, Eddleston, JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 2006;10:R42, https://doi.org/10.1186/cc4854.Search in Google Scholar

24. Garcia-Obregon, S, Azkargorta, M, Seijas, I, Pilar-Orive, J, Borrego, F, Elortza, F, et al.. Identification of a panel of serum protein markers in early stage of sepsis and its validation in a cohort of patients. J Microbiol Immunol Infect 2018;51:465–72, https://doi.org/10.1016/j.jmii.2016.12.002.Search in Google Scholar

25. Llewelyn, MJ, Berger, M, Gregory, M, Ramaiah, R, Taylor, AL, Curdt, I, et al.. Sepsis biomarkers in unselected patients on admission to intensive or high-dependency care. Crit Care 2013;17:R60, https://doi.org/10.1186/cc12588.Search in Google Scholar

26. Matera, G, Puccio, R, Giancotti, A, Quirino, A, Pulicari, MC, Zicca, E, et al.. Impact of interleukin-10, soluble CD25 and interferon-gamma on the prognosis and early diagnosis of bacteremic systemic inflammatory response syndrome: a prospective observational study. Crit Care 2013;17:R64, https://doi.org/10.1186/cc12596.Search in Google Scholar

27. Boeck, L, Graf, R, Eggimann, P, Pargger, H, Raptis, DA, Smyrnios, N, et al.. Pancreatic stone protein: a marker of organ failure and outcome in ventilator-associated pneumonia. Chest 2011;140:925–32, https://doi.org/10.1378/chest.11-0018.Search in Google Scholar

28. Peteiro-Cartelle, FJ, Alvarez-Jorge, A. Dynamic profiles of interleukin-6 and the soluble form of CD25 in burned patients. Burns 1999;25:487–91, https://doi.org/10.1016/s0305-4179(99)00032-7.Search in Google Scholar

Received: 2022-01-25
Revised: 2022-02-12
Accepted: 2022-02-14
Published Online: 2022-02-28
Published in Print: 2022-05-25

© 2022 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Reviews
  3. Statistics in diagnostic medicine
  4. Interferences in immunoassays: review and practical algorithm
  5. EFLM Paper
  6. The value proposition of integrative diagnostics for (early) detection of cancer. On behalf of the EFLM interdisciplinary Task and Finish Group “CNAPS/CTC for early detection of cancer”
  7. General Clinical Chemistry and Laboratory Medicine
  8. Benchmarking medical laboratory performance: survey validation and results for Europe, Middle East, and Africa
  9. Pre-analytical stability of serum biomarkers for neurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-1
  10. Filling in the GAPS: validation of anion gap (AGAP) measurement uncertainty estimates for use in clinical decision making
  11. Implementation and challenges of portable blood gas measurements in air medical transport
  12. Calculation of the estimated glomerular filtration rate using the 2021 CKD-EPI creatinine equation and whole blood creatinine values measured with Radiometer ABL 827 FLEX
  13. Dubiously increased FT4 and FT3 levels in clinically euthyroid patients: clinical finding or analytical pitfall?
  14. Two co-inherited hemoglobin variants revealed by capillary electrophoresis during quantification of glycated hemoglobin
  15. Determination of individual bile acids in acute respiratory distress syndrome reveals a specific pattern of primary and secondary bile acids and a shift to the acidic pathway as an adaptive response to the critical condition
  16. Evaluation of a faecal calprotectin method using the OC-SENSOR PLEDIA
  17. Reference Values and Biological Variations
  18. Reference intervals for Sysmex XN hematological parameters as assessed in the Dutch Lifelines cohort
  19. Cardiovascular Diseases
  20. High incidence of discrepancies in new Siemens assay – a comparison of cardiac troponin I assays
  21. Infectious Diseases
  22. Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals
  23. The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers
  24. Continuous monitoring of SARS-CoV-2 seroprevalence in children using residual blood samples from routine clinical chemistry
  25. Prognostic significance of soluble CD25 in patients with sepsis: a prospective observational study
  26. Letters to the Editors
  27. Diagnostic accuracy of the ultrasensitive S-PLEX SARS-CoV-2 N electrochemiluminescence immunoassay
  28. Life-threatening autoimmune hemolytic anemia following mRNA COVID-19 vaccination: don’t be too prudent with the red gold
  29. CSF-interleukin 6 for early diagnosis of ventriculitis in a broad intensive care setting
  30. Clearance of macro-TSH from the circulation is slower than TSH
  31. Biological variation and reference change value as decision criteria in clinical use of tumor biomarkers. Are they really useful?
  32. Testing for anti-Müllerian hormone: analytical performances and usability of a point-of-care assay
  33. Diagnostic performance characteristics of the Quanta Flash Rheumatoid Factor assay in a consecutive Dutch patient cohort
  34. Trimester-specific reference values for the anticardiolipin antibody by chemiluminescence immunoassay in healthy pregnancy
  35. Congress Abstracts
  36. 4th National Point of Care Testing Symposium
Downloaded on 12.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2022-0068/html
Scroll to top button